Regeneron cuts White House pricing deal, offers new gene therapy for free
The White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.
The White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.
Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Advancing pressure protection in biopharma: how integrated bypass technology elevates single-use pump design
CinnaGen Enters EU Market with EMA Approval for Zandoriah®
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential